Five Younger Dryas black mats in Mexico and their stratigraphic and paleoenvironmental context

The Younger Dryas interval (YD) was a period of widespread, abrupt climate change that occurred between 12,900 and 11,700 cal yr BP (10,900–10,000 14 C BP). Many sites in the Northern Hemisphere preserve a sedimentary record across the onset of the YD interval, including sites investigated in sedimentary basins located in central Mexico (Chapala, Cuitzeo, Acambay), the Basin of Mexico (Tocuila), and northern Mexico (El Cedral). Deposits consist of lacustrine or marginal lake sediments that were deposited during the Pleistocene and the Holocene. At the Tocuila and Acambay sites, Pleistocene fossil vertebrate assemblages, mainly mammoths (Mammuthus columbi), are found in association with a distinctive organic layer, sometimes called the black mat that formed during the YD. At the Chapala, Cuitzeo, Acambay, and Tocuila sites the black mats contain a suite of distinctive microscopic and mineralogical signatures and are accompanied by a sharp change in the depositional environments as supported by diatom and pollen studies reported here. The signatures include magnetic, Fe-rich microspherules, silica melted droplets with aerodynamic shapes (tektites), large amounts of charcoal, and sometimes nanodiamonds (Cuitzeo), all of which were deposited at the onset of the YD. The geochemistry of the microspherules indicates that they are not anthropogenic, authigenic or of cosmic or volcanic origin, and instead, were produced by melting and quenching of terrestrial sediments. Here, we present the stratigraphy at five field sites, the analyses of magnetic microspherules, including major element composition and scanning electron microscopy images. All of these materials are associated with charcoal and soot, which are distinctive stratigraphic markers for the YD layer at several sites in Mexico. © 2017 Springer Science+Business Media B.V

Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse

Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaig

Sensors and Actuators for the Advanced LIGO+ Upgrade

Advanced Laser Interferometer Gravitational-wave Observatory (LIGO A+) is a major upgrade to LIGO—the Laser Interferometer Gravitational-wave Observatory. For the A+ project, we have developed, produced, and characterized sensors and electronics to interrogate new optical suspensions designed to isolate optics from vibrations. The central element is a displacement sensor with an integrated electromagnetic actuator known as a BOSEM (Birmingham Optical Sensor and ElectroMagnetic actuator) and its readout and drive electronics required to integrate them into LIGO’s control and data system. In this paper, we report on the improvements to the sensors and the testing procedures undertaken to meet the enhanced performance requirements set out by the A+ upgrade to the detectors. The best devices reach a noise level of 4.5 ×10−11m/√Hz at a measurement frequency of 1 Hz, an improvement of 6.7 times over standard devices

Survival from testicular cancer in England and Wales up to 2001

www.bjcancer.com For many years testicular cancer has been the prime example of the tumour that is chemocurable, even when metastatic. The disappointment in oncology is that these results have so far not been replicated in the more common solid tumours. Why this should be is not clear but germ-cell tumours retain sensitivity to chemotherapy in vitro and a number of mechanisms including reduced DNA repair capacity and proneness to apoptosis have been proposed (Mayer et al, 2003). Most patients with testicular cancer present after finding a lump in the testicle that may or may not be painful. A small proportion of patients present with symptoms of metastatic disease. With the exception of some patients with metastatic disease, initial treatment after first assessment is to remove the tumour by inguinal orchidectomy. Patients are staged by tumour marke

Разработка компьютерной модели элементов системы безопасности

The treatment of patients with Stage I-II seminoma has changed considerably in the past decade, and in November 2009, an International Consensus meeting was held under the sponsorship of the Union for International Cancer Control (UICC), Société Internationale d'Urologie (SIU), and International Consultation on Urological Diseases (ICUD) to review recent updates in the published data and develop international consensus guidelines on the treatment of this group of patients. In Stage I disease, the consensus conference recommended that patients should be informed of all treatment options, including the potential benefits and side effects of each treatment. It was agreed that this discussion should include a review of the possible salvage treatment effects. In addition, in patients willing and able to adhere to a surveillance program, this should be considered the management option of choice (assuming facilities are available for suitable monitoring). For Stage IIA disease, the consensus conference recommended that radiotherapy should be considered the standard treatment in the absence of contraindications. For Stage IIB disease, chemotherapy or radiotherapy were considered reasonable treatment approaches, and for Stage IIC disease, chemotherapy should be considered the standard treatment approach. For patients with a residual mass after chemotherapy, the consensus conference noted that patients with masses 3 cm in diameter could be considered for immediate surgery or close observation. It was also noted that surgery in this setting is technically challenging and could be associated with greater morbidity than in patients with nonseminomatous tumors